About this Journal Submit a Manuscript Table of Contents
Epilepsy Research and Treatment
Volume 2013 (2013), Article ID 124934, 20 pages
http://dx.doi.org/10.1155/2013/124934
Review Article

Metabolic Causes of Epileptic Encephalopathy

Department of Neurology, Children’s National Medical Center, 111 Michigan Avnue, Washington, DC 20010, USA

Received 22 February 2013; Accepted 16 April 2013

Academic Editor: Giangennaro Coppola

Copyright © 2013 Joe Yuezhou Yu and Phillip L. Pearl. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Köker, S. W. Sauer, G. F. Hoffmann, I. Müller, M. A. Morath, and J. G. Okun, “Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism,” Journal of Inherited Metabolic Disease, vol. 31, no. 2, pp. 194–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. L. Pearl, Inherited Metabolic Epilepsies, Demos Medical, New York, NY, USA, 2013.
  3. R. Biancheri, R. Cerone, M. C. Schiaffino et al., “Cobalamin (Cbl) C/D deficiency: clinical, neurophysiological and neuroradiologic findings in 14 cases,” Neuropediatrics, vol. 32, no. 1, pp. 14–22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Fenton, R. Gravel, and D. Rosenblatt, “Disorders of propionate and methylmalonate metabolism,” in The Metabolic & Molecular Basis of Inherited Disease, C. Scriver, A. Beaudert, W. Sly, et al., Eds., pp. 2165–2193, McGraw-Hill, New York, NY, USA, 2001.
  5. L. A. Azuar, J. M. P. Viǹas, P. S. Crespo, J. A. P. Perera, and M. T. L. Echeverría, “Infantile spasms as the first manifestation of propionic acidemia,” Anales de Pediatria, vol. 63, no. 6, pp. 548–550, 2005. View at Scopus
  6. E. Haberlandt, C. Canestrini, M. Brunner-Krainz et al., “Epilepsy in patients with propionic acidemia,” Neuropediatrics, vol. 40, no. 3, pp. 120–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. I. Zafeiriou, P. Augoustides-Savvopoulou, D. Haas et al., “Ethylmalonic encephalopathy: Clinical and biochemical observations,” Neuropediatrics, vol. 38, no. 2, pp. 78–82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Stigsby, S. M. Yarworth, Z. Rahbeeni et al., “Neurophysiologic correlates of organic acidemias: a survey of 107 patients,” Brain and Development, vol. 16, pp. 125–144, 1994. View at Scopus
  9. J. Brismar and P. T. Ozand, “CT and MR of the brain in the diagnosis of organic acidemias. Experiences from 107 patients,” Neuropediatrics, vol. 40, no. 3, pp. 120–125, 2009.
  10. P. T. Ozand, A. Al Aqeel, G. Gascon, J. Brismar, E. Thomas, and H. Gleispach, “3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency in Saudi Arabia,” Journal of Inherited Metabolic Disease, vol. 14, no. 2, pp. 174–188, 1991. View at Scopus
  11. E. Neumaier-Probst, I. Harting, A. Seitz, C. Ding, and S. Kölker, “Neuroradiological findings in glutaric aciduria type I (glutaryl-CoA dehydrogenase deficiency),” Journal of Inherited Metabolic Disease, vol. 27, no. 6, pp. 869–876, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. A. Strauss, E. G. Puffenberger, D. L. Robinson, and D. H. Morton, “Type I glutaric aciduria, part 1: natural history of 77 patients,” American Journal of Medical Genetics C, vol. 121, no. 1, pp. 38–52, 2003. View at Scopus
  13. S. Kolker, E. Christensen, J. Leonard, et al., “Diagnosis and managament of glutaric aciduria type I-revised recommendations,” Journal of Inherited Metabolic Disease, vol. 34, no. 3, pp. 677–694, 2011.
  14. V. M. McClelland, D. B. Bakalinova, C. Hendriksz, and R. P. Singh, “Glutaric aciduria type 1 presenting with epilepsy,” Developmental Medicine and Child Neurology, vol. 51, no. 3, pp. 235–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. U. F. H. Engelke, B. Kremer, L. A. J. Kluijtmans et al., “NMR spectroscopic studies on the late onset form of 3-methylglutaconic aciduria type I and other defects in leucine metabolism,” NMR in Biomedicine, vol. 19, no. 2, pp. 271–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Illsinger, T. Lücke, J. Zschocke, K. M. Gibson, and A. M. Das, “3-Methylglutaconic aciduria type I in a boy with fever-associated seizures,” Pediatric Neurology, vol. 30, no. 3, pp. 213–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Arun, C. N. Madhavarao, J. R. Moffett et al., “Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease,” Journal of Inherited Metabolic Disease, vol. 33, no. 3, pp. 195–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. M. Canavan, “Schilder's encephalitis periaxialis diffusa,” Archives of Neurology and Psychiatry, vol. 25, no. 2, pp. 299–308, 1931.
  19. R. Segel, Y. Anikster, S. Zevin et al., “A safety trial of high dose glyceryl triacetate for Canavan disease,” Molecular Genetics and Metabolism, vol. 103, no. 3, pp. 203–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Chen, W. L. Nyhan, C. Jakobs et al., “L-2-hydroxyglutaric aciduria: neuropathological correlations and first report of severe neurodegenerative disease and neonatal death,” Journal of Inherited Metabolic Disease, vol. 19, no. 3, pp. 335–343, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. Barth, R. J. A. Wanders, H. R. Scholte et al., “L-2-hydroxyglutaric aciduria and lactic acidosis,” Journal of Inherited Metabolic Disease, vol. 21, no. 3, pp. 251–254, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Kerrigan, K. Aleck, T. J. T, et al., “Fumaric aciduria: clinical and imaging features,” Annals of Neurology, vol. 47, no. 5, pp. 583–588, 2000.
  23. D. T. Chuang and V. Shih, “Maple syrup urine disease (branched chain ketoaciduria),” in The Metabolic and Molecular Basis of Inherited Disease, C. Scriver, A. Beaudet, W. Sly, et al., Eds., pp. 1971–2005, McGraw-Hill, New York, NY, USA, 2001.
  24. C. Sansaricq, S. Pardo, M. Balwani, M. Grace, and K. Raymond, “Biochemical and molecular diagnosis of lipoamide dehydrogenase deficiency in a North American Ashkenazi Jewish family,” Journal of Inherited Metabolic Disease, vol. 29, no. 1, pp. 203–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. P. L. Pearl, C. Jakobs, and K. M. Gibson, “Disorders of beta- and gamma-amino acids in free and peptide-linked forms,” in Online Molecular and Metabolic Bases of Inherited Disease, D. Valle, A. Beaudet, B. Vogelstein, et al., Eds., 2007, http://www.ommbid.com/.
  26. I. Knerr, K. M. Gibson, G. Murdoch et al., “Neuropathology in succinic semialdehyde dehydrogenase deficiency,” Pediatric Neurology, vol. 42, no. 4, pp. 255–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. P. L. Pearl, K. M. Gibson, M. A. Cortez et al., “Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men,” Journal of Inherited Metabolic Disease, vol. 32, no. 3, pp. 343–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Rinaldo, D. Matern, and M. J. Bennett, “Fatty acid oxidation disorders,” Annual Review of Physiology, vol. 64, pp. 477–502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Tein, “Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy,” Journal of Child Neurology, vol. 17, supplement 3, pp. S57–S82, 2002. View at Scopus
  30. U. Spiekerkoetter, J. Bastin, M. Gillingham, A. Morris, F. Wijburg, and B. Wilcken, “Current issues regarding treatment of mitochondrial fatty acid oxidation disorders,” Journal of Inherited Metabolic Disease, vol. 33, no. 5, pp. 555–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Morris and U. Spiekerkoetter, “Disorders of mitochondrial fatty acid oxidation and related metabolic pathways,” in Inborn Metabolic Diseases: Diagnosis and Treatment, J. Saudubray, G. vanden Berghe, and J. Walter, Eds., pp. 201–214, Springer, Berlin, Germany, 2012.
  32. D. S. Khurana, L. Salganicoff, J. J. Melvin et al., “Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies,” Neuropediatrics, vol. 39, no. 1, pp. 8–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. H. Cohen, P. F. Chinnery, and W. C. Copeland, “POLG-related disorders,” in Genereviews, R. A. Pagon, T. D. Bird, C. R. Dolan, et al., Eds., pp. 1993–2010, University of Washington, Seattle, Wash, USA, 1993.
  34. N. I. Wolf, S. Rahman, B. Schmitt et al., “Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features,” Epilepsia, vol. 50, no. 6, pp. 1596–1607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Finsterer, “Inherited mitochondrial neuropathies,” Journal of the Neurological Sciences, vol. 304, no. 1-2, pp. 9–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. DiMauro and E. A. Schon, “Mitochondrial disorders in the nervous system,” Annual Review of Neuroscience, vol. 31, pp. 91–123, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D. R. Johns, J. Flier, D. Moller et al., “Mitochondrial DNA and disease,” The New England Journal of Medicine, vol. 333, no. 10, pp. 638–644, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Canafoglia, S. Franceschetti, C. Antozzi et al., “Epileptic phenotypes associated with mitochondrial disorders,” Neurology, vol. 56, no. 10, pp. 1340–1346, 2001. View at Scopus
  39. S. DiMauro and D. C. De Vivo, “Genetic heterogeneity in Leigh syndrome,” Annals of Neurology, vol. 40, no. 1, pp. 5–7, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. S. E. Sabbagh, A. S. Lebre, N. Bahi-Buisson et al., “Epileptic phenotypes in children with respiratory chain disorders,” Epilepsia, vol. 51, no. 7, pp. 1225–1235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. S. Rosenblatt and W. A. Fenton, “Inherited disorders of folate and cobalamin transport and metabolism,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, et al., Eds., p. 3897, McGraw-Hill, New York, NY, USA, 8th edition, 2001.
  42. M. Dougados, J. Zittoun, D. Laplane, and P. Castaigne, “Folate metabolism disorder in Kearns-Sayre syndrome,” Annals of Neurology, vol. 13, no. 6, p. 687, 1983. View at Scopus
  43. M. Pineda, A. Ormazabal, E. López-Gallardo et al., “Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion,” Annals of Neurology, vol. 59, no. 2, pp. 394–398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. O. Hasselmann, N. Blau, V. T. Ramaekers, E. V. Quadros, J. M. Sequeira, and M. Weissert, “Cerebral folate deficiency and CNS inflammatory markers in Alpers disease,” Molecular Genetics and Metabolism, vol. 99, no. 1, pp. 58–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Moretti, T. Sahoo, K. Hyland et al., “Cerebral folate deficiency with developmental delay, autism, and response to folinic acid,” Neurology, vol. 64, no. 6, pp. 1088–1090, 2005. View at Scopus
  46. J. Jaeken, “Disorders of serine and proline metabolism,” in Inborn Metabolic Diseases: Diagnosis and Treatment, J. Saudubray, G. vanden Berghe, and J. Walter, Eds., pp. 360–361, Springer, Berlin, Germany, 2012.
  47. L. Tabatabaie, L. W. Klomp, R. Berger, and T. J. de Koning, “l-Serine synthesis in the central nervous system: a review on serine deficiency disorders,” Molecular Genetics and Metabolism, vol. 99, no. 3, pp. 256–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. T. J. D. Koning, L. W. J. Klomp, A. C. C. V. Oppen et al., “Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency,” The Lancet, vol. 364, no. 9452, pp. 2221–2222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. T. J. De Koning, J. Jaeken, M. Pineda, L. Van Maldergem, B. T. Poll-The, and M. S. Van der Knaap, “Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency,” Neuropediatrics, vol. 31, no. 6, pp. 287–292, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Shimomura, F. Hörster, H. de Wet et al., “A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain,” Neurology, vol. 69, no. 13, pp. 1342–1349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. A. L. Gloyn, E. R. Pearson, J. F. Antcliff et al., “Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes,” The New England Journal of Medicine, vol. 350, no. 18, pp. 1838–1849, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Proks, A. L. Arnold, J. Bruining et al., “A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes,” Human Molecular Genetics, vol. 15, no. 11, pp. 1793–1800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. F. M. Ashcroft, “ATP-sensitive K+ channels and disease: from molecule to malady,” American Journal of Physiology, vol. 293, no. 4, pp. E880–E889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. L. C. Gurgel, F. Crispim, M. H. S. Noffs, E. Belzunces, M. A. Rahal, and R. S. Moisés, “Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene,” Diabetes Care, vol. 30, no. 11, p. e108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Mlynarski, A. I. Tarasov, A. Gach et al., “Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11,” Nature Clinical Practice Neurology, vol. 3, no. 11, pp. 640–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. M. A. Sperling and R. K. Menon, “Hyperinsulinemic hypoglycemia of infancy: recent insights into ATP-sensitive potassium channels, sulfonylurea receptors, molecular mechanisms, and treatment,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 4, pp. 695–708, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Bahi-Buisson, E. Roze, C. Dionisi et al., “Neurological aspects of hyperinsulinism-hyperammonaemia syndrome,” Developmental Medicine and Child Neurology, vol. 50, no. 12, pp. 945–949, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. F. P. Errazquin, J. S. Fernández, G. G. Martín, M. I. C. Muñoz, and M. R. Acebal, “Hyperinsulinism and hyperammonaemia syndrome and severe myoclonic epilepsy of infancy,” Neurologia, vol. 26, no. 4, pp. 248–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Bahi-Buisson, S. El Sabbagh, C. Soufflet et al., “Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase,” Seizure, vol. 17, no. 7, pp. 658–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. A. Palladino and C. A. Stanley, “The hyperinsulinism/hyperammonemia syndrome,” Reviews in Endocrine and Metabolic Disorders, vol. 11, no. 3, pp. 171–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Brockmann, “The expanding phenotype of GLUT1-deficiency syndrome,” Brain and Development, vol. 31, no. 7, pp. 545–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. D. C. De Vivo, R. R. Trifiletti, R. I. Jacobson, G. M. Ronen, R. A. Behmand, and S. I. Harik, “Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay,” The New England Journal of Medicine, vol. 325, no. 10, pp. 703–709, 1991. View at Scopus
  63. M. Rotstein, K. Engelstad, H. Yang et al., “Glut1 deficiency: inheritance pattern determined by haploinsufficiency,” Annals of Neurology, vol. 68, no. 6, pp. 955–958, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Wang, J. M. Pascual, and D. De Vivo, “Glucose transporter type 1 deficiency syndrome,” in GeneReviews, R. A. Pagon, T. D. Bird, C. R. Dolar, et al., Eds., pp. 1993–2002, University of Washington, Seattle, Wash, USA, 2009, Bookshelf ID: NBK1217.
  65. P. B. Mills, E. Struys, C. Jakobs et al., “Mutations in antiquitin in individuals with pyridoxine-dependent seizures,” Nature Medicine, vol. 12, no. 3, pp. 307–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. G. J. Basura, S. P. Hagland, A. M. Wiltse, and S. M. Gospe, “Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry,” European Journal of Pediatrics, vol. 168, no. 6, pp. 697–704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. R. C. Gallagher, J. L. K. Van Hove, G. Scharer et al., “Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy,” Annals of Neurology, vol. 65, no. 5, pp. 550–556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. P. B. Mills, E. J. Footitt, K. A. Mills et al., “Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency),” Brain, vol. 133, no. 7, pp. 2148–2159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. P. L. Pearl and S. M. Gospe, “Pyridoxal phosphate dependency, a newly recognized treatable catastrophic epileptic encephalopathy,” Journal of Inherited Metabolic Disease, vol. 30, no. 1, pp. 2–4, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Baxter, “Recent insights into pre- and postnatal pyridoxal phosphate deficiency, a treatable metabolic encephalopathy,” Developmental Medicine and Child Neurology, vol. 52, no. 7, pp. 597–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. P. B. Mills, R. A. H. Surtees, M. P. Champion et al., “Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase,” Human Molecular Genetics, vol. 14, no. 8, pp. 1077–1086, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. M. L. Summar, D. Dobbelaere, S. Brusilow, and B. Lee, “Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes,” Acta Paediatrica, vol. 97, no. 10, pp. 1420–1425, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. M. L. Summar, “Urea cycle disorders overview,” in GeneReviews, R. A. Pagon, T. D. Bird, C. R. Dolan, et al., Eds., pp. 1993–2002, University of Washington, Seattle, Wash, USA, 2005, Bookshelf ID: NBK1217.
  74. M. J. C. C. Dealberto and F. F. A. Sarazin, “Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: a case report in the psychiatric setting,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 20, no. 3, pp. 369–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. J. M. van de Kamp, G. M. S. Mancini, P. J. W. Pouwels et al., “Clinical features and X-inactivation in females heterozygous for creatine transporter defect,” Clinical Genetics, vol. 79, no. 3, pp. 264–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Nasrallah, M. Feki, and N. Kaabachi, “Creatine and creatine deficiency syndromes: biochemical and clinical aspects,” Pediatric Neurology, vol. 42, no. 3, pp. 163–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Fons, A. Sempere, F. X. Sanmartí et al., “Epilepsy spectrum in cerebral creatine transporter deficiency: letters/commentary,” Epilepsia, vol. 50, no. 9, pp. 2168–2170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. V. Leuzzi, “Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis, and treatment,” Journal of Child Neurology, vol. 17, supplement 3, pp. S89–S97, 2002. View at Scopus
  79. N. M. Verhoeven, G. S. Salomons, and C. Jakobs, “Laboratory diagnosis of defects of creatine biosynthesis and transport,” Clinica Chimica Acta, vol. 361, no. 1-2, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Hamosh and M. V. Johnston, “Nonketotic hyperglycinemia,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Sciver, A. L. Beaudet, W. S. Sly, et al., Eds., pp. 2065–2078, McGraw-Hill, New York, NY, USA, 8th edition, 2001.
  81. J. E. Hoover-Fong, S. Shah, J. L. K. van Hove, D. Applegarth, J. Toone, and A. Hamosh, “Natural history of nonketotic hyperglycinemia in 65 patients,” Neurology, vol. 64, no. 10, pp. 1847–1853, 2004. View at Scopus
  82. S. Rossi, I. Daniele, P. Bastrenta, M. Mastrangelo, and G. Lista, “Early myoclonic encephalopathy and nonketotic hyperglycinemia,” Pediatric Neurology, vol. 41, no. 5, pp. 371–374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Bonioli, “Combined deficiency of xanthine oxidase and sulphite oxidase due to a deficiency of molybdenum cofactor,” Journal of Inherited Metabolic Disease, vol. 19, no. 5, pp. 700–701, 1996. View at Scopus
  84. J. L. Johnson and M. Duran, “Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Sciver, A. L. Beaudet, W. S. Sly, et al., Eds., pp. 2163–3177, McGraw-Hill, New York, NY, USA, 2001.
  85. A. H. Van Gennip, N. G. G. M. Abeling, A. E. M. Stroomer, H. Overmars, and H. D. Bakker, “The detection of molybdenum cofactor deficiency: clinical symptomatology and urinary metabolite profile,” Journal of Inherited Metabolic Disease, vol. 17, no. 1, pp. 142–145, 1994. View at Scopus
  86. S. D. Sie, R. C. de Jonge, H. J. Blom, et al., “Chronological changes of the amplitude-integrated EEG in a neonate with molybdenum cofactor deficiency,” Journal of Inherited Metabolic Disease, 2010. View at Publisher · View at Google Scholar
  87. K. Vijayakumar, R. Gunny, S. Grunewald, et al., “Clinical neuroimaging features and outcome in molybdenum cofactor deficiency,” Pediatric Neurology, vol. 45, pp. 246–252, 2011.
  88. A. N. Prasad, C. A. Rupar, and C. Prasad, “Methylenetetrahydrofolate reductase (MTHFR) deficiency and infantile epilepsy,” Brain and Development, vol. 33, pp. 758–769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. P. M. Ueland, P. I. Holm, and S. Hustad, “Betaine: a key modulator of one-carbon metabolism and homocysteine status,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 10, pp. 1069–1075, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Ciardo, C. Salerno, and P. Curatolo, “Neurologic aspects of adenylosuccinate lyase deficiency,” Journal of Child Neurology, vol. 16, no. 5, pp. 301–308, 2001. View at Scopus
  91. T. Mizuno, “Long-term follow-up of ten patients with Lesch-Nyhan syndrome,” Neuropediatrics, vol. 17, no. 3, pp. 158–161, 1986. View at Scopus
  92. J. K. Sass, H. H. Itabashi, and R. A. Dexter, “Juvenile gout with brain involvement,” Archives of Neurology, vol. 13, no. 6, pp. 639–655, 1965. View at Scopus
  93. J. Vajsar and H. Schachter, “Walker-Warburg syndrome,” Orphanet Journal of Rare Diseases, vol. 1, no. 1, article 29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Warburg, “Hydrocephaly, congenital retinal nonattachment, and congenital falciform fold,” American Journal of Ophthalmology, vol. 85, no. 1, pp. 88–94, 1978. View at Scopus
  95. Y. Fukuyama, M. Osawa, and H. Suzuki, “Congenital progressive muscular dystrophy of the Fukuyama type—clinical, genetic and pathological considerations,” Brain and Development, vol. 3, no. 1, pp. 1–29, 1981. View at Scopus
  96. E. Mercuri, H. Topaloglu, M. Brockington et al., “Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations,” Archives of Neurology, vol. 63, no. 2, pp. 251–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Jalanko and T. Braulke, “Neuronal ceroid lipofuscinoses,” Biochimica et Biophysica Acta, vol. 1793, no. 4, pp. 697–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. S. E. Mole and R. E. Williams, “Neuronal ceroid-lipofuscinoses,” in GeneReviews, R. A. Pagon, T. C. Bird, C. R. Dolan, et al., Eds., pp. 1993–2001, University of Washington, Seattle, Wash, USA, 2005.
  99. P. Santavuori, S. L. Vanhanen, and T. Autti, “Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders,” European Journal of Paediatric Neurology A, vol. 5, pp. 157–161, 2001. View at Scopus
  100. E. Sidransky, “Gaucher disease: complexity in a “simple” disorder,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 6–15, 2004.
  101. A. Tylki-Szymańska, A. Vellodi, A. El-Beshlawy, J. A. Cole, and E. Kolodny, “Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry,” Journal of Inherited Metabolic Disease, vol. 33, no. 4, pp. 339–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. G. H. B. Maegawa, T. Stockley, M. Tropak et al., “The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported,” Pediatrics, vol. 118, no. 5, pp. e1550–e1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Gressens, “Pathogenesis of migration disorders,” Current Opinion in Neurology, vol. 19, no. 2, pp. 135–140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. G. V. Raymond, “Peroxisomal disorders,” Current Opinion in Neurology, vol. 14, no. 6, pp. 783–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Shimozawa, “Molecular and clinical aspects of peroxisomal diseases,” Journal of Inherited Metabolic Disease, vol. 30, no. 2, pp. 193–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. A. L. White, P. Modaff, F. Holland-Morris, and R. M. Pauli, “Natural history of rhizomelic chondrodysplasia punctata,” American Journal of Medical Genetics A, vol. 118, no. 4, pp. 332–342, 2003. View at Scopus
  107. M. Prust, J. Wang, H. Morizono, et al., “GFAP mutations, age at onset, and clinical subtypes in Alexander disease,” Neurology, vol. 77, no. 13, pp. 1287–1294, 2011.
  108. L. Papetti, P. Parisi, V. Leuzzi, et al., “Metabolic epilepsy: an update,” Brain and Development, 2012. View at Publisher · View at Google Scholar